Medtronic (NYSE:MDT) experienced a price increase of 7% over the last quarter, which may have been influenced by notable ...

Used for diagnosing gastroesophageal reflux, the devices may not attach or detach correctly, potentially causing serious ...

The company named Chad Spooner CFO of MiniMed ahead of plans to spin out the diabetes unit into a separate public firm.

Medtronic PLC closed 7.97% below its 52-week high of $96.25, which the company achieved on March 10th.

CMS proposed Medicare coverage for Medtronic's renal denervation therapy for high blood pressure, signaling a key step toward ...

Medtronic is studying the use of its nitinol-enabled Symplicity Spyral renal denervation (RDN) catheter combined with hepatic ...

Goldman Sachs analyst David Roman reiterated a Sell rating on Medtronic today and set a price target of $78.00. The company’s shares closed today at $89.92. Take advantage of TipRanks Premium at 50% ...

Nearly 70 years into her history, Barbie is still undergoing regular makeovers. | Nearly 70 years into her history, Barbie is ...

Medtronic and Recor Medical both issued statements supporting new Medicare coverage for their respective renal denervation ...

Medtronic's growth strategies, dividend stability, and innovation focus amidst debt concerns and market risks. Click here to ...

Medtronic has historically held roughly 50% share in its core heart devices. It's also the market leader in spinal products, insulin pumps, and neuromodulators for chronic pain.

Medtronic's margin inflection from the Diabetes spin-off and strong innovation pipeline support major upside. Find out why ...